2nd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 2245, S. 296, "Preserving Access to Life-Saving Medications Act," all provisions. Contacts concerning Food and Drug Administration (FDA) authority to manage drug shortages. Communication to the FDA on Medication guideline distribution and the REMS program, drug shortages. Labor-Health and Human Services appropriations, fiscal year 2010 and 2011; support for Administration's request for FDA funding. Contacts concerning funding for section 3503 of Affordable Care Act (P.L. 111-148). Communication to the Office of the National Coordinator for Health Information Technology regarding its strategic plan. Communication to Office of Management and Budget concerning consumer medication information.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); Office of Management & Budget (OMB)

Bills named: H.R. 2245 (112th), S. 296 (112th)

Medicare/Medicaid MMM

Communication with Centers for Medicare and Medicaid Services regarding administration of medication to inpatients within 30 minutes of scheduled dosage time. Communication with CMS regarding Accountable Care Orgaizations and the Shared Savings Program, Value Based Purchasing Program, Innovation Center, and hospital inpatient prospective payment system.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: SENATE; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES

Pharmacy PHA

Communication with Government Accountability Office concerning its study (required under section 7103, P.L. 111-148) on improving the 340B drug discount program.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Food & Drug Administration (FDA); Government Accountability Office (GAO); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.